Home > Boards > US Listed > Biotechs > Soligenix, Inc. (SNGX)

https://www.soligenix.com/pipeline-programs/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
INTHEKNOW1 Member Profile
Member Level 
Followed By 2,426
Posts 56,837
Boards Moderated 7
Alias Born 06/04/04
160x600 placeholder
Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter PR Newswire (US) - 2/24/2021 7:00:00 AM
Soligenix to Present at the 2021 BIO CEO & Investor Digital Conference PR Newswire (US) - 2/11/2021 7:00:00 AM
Soligenix Receives Hong Kong Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma PR Newswire (US) - 2/1/2021 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 2/1/2021 6:11:35 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/26/2021 5:02:29 PM
Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma PR Newswire (US) - 1/19/2021 7:00:00 AM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 1/15/2021 4:31:29 PM
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in th... PR Newswire (US) - 1/7/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/4/2021 4:31:07 PM
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development PR Newswire (US) - 12/28/2020 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/22/2020 9:16:25 AM
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and... PR Newswire (US) - 12/22/2020 6:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/16/2020 4:31:44 PM
Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing PR Newswire (US) - 12/16/2020 9:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/11/2020 5:05:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/11/2020 5:04:07 PM
Soligenix Demonstrates Extended Protection with its RiVax® Ricin Toxin Vaccine PR Newswire (US) - 12/8/2020 8:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 12/3/2020 4:35:42 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 11/25/2020 7:32:39 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/25/2020 7:30:59 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2020 7:16:17 AM
Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results PR Newswire (US) - 11/12/2020 7:00:00 AM
Soligenix Invited to Present at Upcoming Virtual Investor Conferences PR Newswire (US) - 11/10/2020 7:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 11/6/2020 4:32:56 PM
Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma PR Newswire (US) - 10/22/2020 9:00:00 AM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
© 2021 InvestorsHub.com, Inc.
Consent Preferences